Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination.

De Vleeschouwer S, Ardon H, Van Calenbergh F, Sciot R, Wilms G, van Loon J, Goffin J, Van Gool S.

Cancer Immunol Immunother. 2012 Nov;61(11):2105-12. doi: 10.1007/s00262-012-1271-z. Epub 2012 May 8.

PMID:
22565485
2.

Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.

Müller K, Henke G, Pietschmann S, van Gool S, De Vleeschouwer S, von Bueren AO, Compter I, Friedrich C, Matuschek C, Klautke G, Kortmann RD, Hundsberger T, Baumert BG.

J Neurooncol. 2015 Sep;124(2):325-32. doi: 10.1007/s11060-015-1844-8. Epub 2015 Jun 13.

PMID:
26070556
3.

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.

De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW.

Clin Cancer Res. 2008 May 15;14(10):3098-104. doi: 10.1158/1078-0432.CCR-07-4875.

4.

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.

Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F, Menten J, Clement P, Debiec-Rychter M, De Vleeschouwer S.

Cancer Immunol Immunother. 2012 Nov;61(11):2033-44. doi: 10.1007/s00262-012-1261-1. Epub 2012 Apr 22.

PMID:
22527250
5.

A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.

Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T, Yang WK.

J Clin Neurosci. 2011 Aug;18(8):1048-54. doi: 10.1016/j.jocn.2010.11.034. Epub 2011 Jun 28.

PMID:
21715171
6.

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study.

Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Kühl J, Demaerel P, Warmuth-Metz M, Flamen P, Van Calenbergh F, Plets C, Sörensen N, Opitz A, Van Gool SW.

Br J Cancer. 2004 Nov 1;91(9):1656-62.

7.

Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis.

Videtic GM, Gaspar LE, Zamorano L, Stitt LW, Fontanesi J, Levin KJ.

Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):963-8.

PMID:
11704318
8.

Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.

Park CK, Lee SH, Han JH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung HW.

BMC Cancer. 2009 Dec 18;9:450. doi: 10.1186/1471-2407-9-450.

9.

Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?

Nieder C, Nestle U, Motaref B, Walter K, Niewald M, Schnabel K.

Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):297-302.

PMID:
10661335
10.

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.

Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, Tanaka R.

Clin Cancer Res. 2005 Jun 1;11(11):4160-7.

11.

Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours.

Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, Rutkowski S, Wolff JE, Van Gool SW.

Pediatr Blood Cancer. 2010 Apr;54(4):519-25. doi: 10.1002/pbc.22319.

PMID:
19852061
12.

Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06.

Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, Curran WJ Jr.

Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5.

PMID:
9422557
13.

Recursive partitioning analysis classifications I and II: applicability evaluated in a randomized trial for resected single brain metastases.

Regine WF, Rogozinska A, Kryscio RJ, Tibbs PA, Young AB, Patchell RA.

Am J Clin Oncol. 2004 Oct;27(5):505-9.

PMID:
15596921
14.
15.

Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele.

Iwami K, Shimato S, Ohno M, Okada H, Nakahara N, Sato Y, Yoshida J, Suzuki S, Nishikawa H, Shiku H, Natsume A, Wakabayashi T.

Cytotherapy. 2012 Jul;14(6):733-42. doi: 10.3109/14653249.2012.666633. Epub 2012 Mar 16.

PMID:
22424217
16.

Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC).

Komaki R, Scott CB, Byhardt R, Emami B, Asbell SO, Russell AH, Roach M, Parliament MB, Gaspar LE.

Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):263-7.

PMID:
9788403
17.

Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas.

Videtic GM, Gaspar LE, Zamorano L, Fontanesi J, Levin KJ, Kupsky WJ, Tekyi-Mensah S.

Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):687-92.

PMID:
10524423
18.

Validity of three recently proposed prognostic grading indexes for breast cancer patients with radiosurgically treated brain metastases.

Yamamoto M, Kawabe T, Higuchi Y, Sato Y, Barfod BE, Kasuya H, Urakawa Y.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1110-5. doi: 10.1016/j.ijrobp.2012.02.040. Epub 2012 Apr 18.

PMID:
22516807
19.

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al.

J Natl Cancer Inst. 1993 May 5;85(9):704-10.

PMID:
8478956
20.

Supplemental Content

Support Center